Coalition Covid-19 Brazil – Randomized trial: Dexamethasone improves outcomes in patients with Acute Respiratory Distress Syndrome and COVID-19

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial – JAMA

Editorial: Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic

Related studies: Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial – JAMA AND Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial – JAMA

Commentary: Inexpensive Steroids Can Save Lives Of Seriously Ill COVID-19 Patients – NPR

Commentary on Twitter

In this RCT, IV #dexamethasone increased the number of ventilator-free days by day 28 vs standard care alone among patients with #COVID19 and moderate or severe ARDS https://t.co/RA9G6LVRlz @ICURevisited @FlaviaSepsis @israelmaia16

— JAMA (@JAMA_current) September 2, 2020